` RKVTF (Rakovina Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

R
RKVTF
vs
S&P 500

Over the past 12 months, RKVTF has underperformed S&P 500, delivering a return of -18% compared to the S&P 500's +16% growth.

Stocks Performance
RKVTF vs S&P 500

Loading
RKVTF
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
RKVTF vs S&P 500

Loading
RKVTF
S&P 500
Difference
www.alphaspread.com

Performance By Year
RKVTF vs S&P 500

Loading
RKVTF
S&P 500
Add Stock

Competitors Performance
Rakovina Therapeutics Inc vs Peers

S&P 500
RKVTF
AMGN
ALNY
ARGX
603259
Add Stock

Rakovina Therapeutics Inc
Glance View

Market Cap
32m USD
Industry
N/A

Rakovina Therapeutics, Inc. focuses on the development of new cancer treatments based on novel DNA-damage response technologies. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2020-02-07. The Company’s research programs include kt-2000, kt-3000 and kt-4000 The kt-2000 next generation PARP-inhibitors. The kt-3000 class drug candidates are rationally designed to overcome treatment resistance by selectively downregulating deoxyribonucleic acid (DNA) double-strand (DSB) repair mechanisms while enhancing PARP inhibitor activity. The kt-4000 series lead candidates release a potent methylation agent causing damage to a tumor cell’s DNA while also inhibiting DNA-damage repair mechanisms to cancer cell death.

RKVTF Intrinsic Value
0.04 USD
Overvaluation 91%
Intrinsic Value
Price
R
Back to Top